About: Sufotidine

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Sufotidine (INN, USAN, codenamed AH25352) is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant by Glaxo (now GlaxoSmithKline). It was planned to be a follow-up compound to ranitidine (Zantac). When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. Its development was terminated in 1989 from phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents.

Property	Value
dbo:abstract	Sufotidine (INN, USAN, codenamed AH25352) is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant by Glaxo (now GlaxoSmithKline). It was planned to be a follow-up compound to ranitidine (Zantac). When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. Its development was terminated in 1989 from phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents. (en)
dbo:casNumber	80343-63-1
dbo:fdaUniiCode	56B0591Y76
dbo:kegg	D05939
dbo:pubchem	71763
dbo:thumbnail	wiki-commons:Special:FilePath/Sufotidine.svg?width=300
dbo:wikiPageID	49078162 (xsd:integer)
dbo:wikiPageLength	4263 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	981987416 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Sulfones dbc:Abandoned_drugs dbc:Amines dbc:Phenol_ethers dbc:Piperidines dbc:Triazoles dbr:GlaxoSmithKline dbr:Sulfone dbr:Receptor_antagonist dbr:Peptic_ulcer dbr:Lavoltidine dbr:International_Nonproprietary_Name dbc:H2_receptor_antagonists dbr:H2_receptor dbr:Omeprazole dbr:Ranitidine dbr:United_States_Adopted_Name dbr:Phases_of_clinical_research dbr:Proton_pump_inhibitor dbr:File:Sufotidine_synthesis.png
dbp:atcPrefix	None (en)
dbp:c	20 (xsd:integer)
dbp:casNumber	80343 (xsd:integer)
dbp:chemspiderid	64802 (xsd:integer)
dbp:h	31 (xsd:integer)
dbp:iupacName	2 (xsd:integer)
dbp:kegg	D05939 (en)
dbp:legalStatus	Development terminated (en)
dbp:n	5 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	71763 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:s	1 (xsd:integer)
dbp:smiles	CN1CNCCCOC2=CC=CCCN3CCCCC3 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	JEYKZWRXDALMNG-UHFFFAOYSA-N (en)
dbp:unii	56 (xsd:integer)
dbp:width	300 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Histaminergics dbt:H2-receptor_antagonist
dcterms:subject	dbc:Sulfones dbc:Abandoned_drugs dbc:Amines dbc:Phenol_ethers dbc:Piperidines dbc:Triazoles dbc:H2_receptor_antagonists
gold:hypernym	dbr:Antagonist
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Sufotidine (INN, USAN, codenamed AH25352) is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant by Glaxo (now GlaxoSmithKline). It was planned to be a follow-up compound to ranitidine (Zantac). When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. Its development was terminated in 1989 from phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents. (en)
rdfs:label	Sufotidine (en)
owl:sameAs	yago-res:Sufotidine wikidata:Sufotidine https://global.dbpedia.org/id/2PSvr
prov:wasDerivedFrom	wikipedia-en:Sufotidine?oldid=981987416&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Sufotidine.svg wiki-commons:Special:FilePath/Sufotidine_synthesis.png
foaf:isPrimaryTopicOf	wikipedia-en:Sufotidine
is dbo:wikiPageWikiLink of	dbr:Lavoltidine dbr:List_of_drugs:_Suc–Sul
is foaf:primaryTopic of	wikipedia-en:Sufotidine

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License